|
Comparative Study of Chemotherapy for B-Cell Lymphoma
Name of the Trial
Phase I/II Study of Bortezomib Alone or With Etoposide, Prednisone, Vincristine,
Cyclophosphamide, and Doxorubicin (EPOCH) in Patients with Relapsed or
Refractory Diffuse Large B-Cell Lymphoma (NCI-03-C-0096).
See the protocol summary.
 |
Dr. Wyndham Wilson
Principal Investigator |
Principal Investigator
Dr. Wyndham Wilson, NCI Center for Cancer Research.
Why This Trial Is Important
B-cell lymphoma is a cancer caused by uncontrolled growth of B cells, white
blood cells that produce the body's disease fighting antibodies. This common
cancer strikes an estimated 41,000 Americans each year.
Bortezomib, one of a new class of targeted anticancer drugs called
proteasome
inhibitors, has shown effectiveness against relapsed (worsening after a period
of improvement) or refractory (treatment-resistant) blood-cell cancers in other
clinical studies. This trial will compare bortezomib alone against bortezomib
added to a chemotherapy combination known as EPOCH (etoposide, prednisone,
vincristine, cyclophosphamide, and doxorubicin) to see which is more effective
in fighting relapsed or refractory large B-cell lymphoma.
“Because bortezomib targets a pathway important in certain types of
diffuse large B-cell lymphoma, we hope that it will make these tumors more
sensitive to chemotherapy and, perhaps, even cause tumors to shrink on their
own” said Dr. Wilson.
“EPOCH already has been shown to be a very good regimen for people with
this disease,” Dr. Wilson added. “With this study, the first to
combine bortezomib and EPOCH, we hope to see the agents work in synergy to
produce even better results.”
Contact Information
This trial is no longer accepting new patients. To locate other clinical trials
for lymphoma, search the NCI database of clinical
trials or call the NCI's Clinical Studies Support
Center (CSSC) at 1-888-NCI-1937. The call is toll free and completely
confidential.
 Back to Top |
